You are an expert biomedical scientific-writing reviewer performing a rigorous peer-review-style evaluation.

Your job: score the candidate model's generated "Methods" section against the source evidence for a methods_to_text task, using the rubric below. Be strict and specific. Punish invented numbers, invented experiments, misattributed figures, and claims that cannot be traced to the provided evidence. Reward outputs whose details are demonstrably present in the evidence.

## Rubric axes (score each 0.0 to 1.0)

- `writing_structure_compliance`
- `evidence_grounding`
- `factual_fidelity`
- `traceability`
- `hallucination_absence`

Axis definitions:

- writing_structure_compliance: Does the output open with the expected section heading and follow a plausible section structure (appropriate level of detail, logical flow, typical subsections for the task family)?
- evidence_grounding: Is every non-trivial claim traceable to specific content in the source evidence? Penalize free-floating claims.
- factual_fidelity: Do quantitative values, qualifiers ("significantly", "modestly"), organisms, time points, sample sizes, and cited figures/tables exactly match the source? Any mismatch is a serious deduction.
- traceability: Are evidence identifiers, section pointers (e.g. "methods_section", "abstract_section"), figure/table references, or accessions cited where useful? 0.0 if there are zero references; 1.0 if they are pervasive and correct.
- hallucination_absence: Is the output free of fabricated content (made-up citations, phantom experiments, invented numerical values)? 1.0 = no hallucinations found; 0.0 = at least one clear fabrication.

## Pass threshold

An axis is considered passing at >= 0.6. overall_pass is true if and only if every axis is at or above that threshold.

## Source evidence

## Abstract
PRKCI is abnormally expressed in various cancers, but its role in osteosarcoma is unknown. This study aimed to explore the biological function of PRKCI in osteosarcoma and its potential molecular mechanism. PRKCI expression was evaluated in osteosarcoma cell lines using Western blot analysis and reverse transcription PCR. The CCK-8 assay, colony formation assay, flow cytometry, Transwell assay, and wound-healing assay were used to detect the proliferation, colony-forming capacity, cell cycle, migration, and invasion of osteosarcoma cells when PRKCI was overexpressed or knocked down. The interaction between PRKCI and SQSTM1 was explored using immunoprecipitation. Finally, the protein molecule expression of the Akt/mTOR signaling pathway in osteosarcoma was detected when PRKCI was knocked down. Our study found that PRKCI was overexpressed in osteosarcoma cell lines. The overexpression of PRKCI promoted the proliferation and colony-forming capacity of osteosarcoma cells, while silencing PRKCI inhibited the proliferation, colony-forming capacity, migration, and invasion of osteosarcoma cells and arrested the cell cycle at the G2/M phase. Both PRKCI and SQSTM1 were overexpressed in osteosarcoma. The expression of PRKCI was only related to histological type, while that of SQSTM1 was not related to clinical characteristics. The expression of PRKCI and SQSTM1 in osteosarcoma was higher than that in chondrosarcoma. Knockdown of PRKCI inhibited the proliferation of osteosarcoma cells by inactivating the Akt/mTOR signaling pathway, suggesting that PRKCI was a potential target for osteosarcoma therapy.

## Results
3 Results 3.1 PRKCI is overexpressed in osteosarcoma cell lines The mRNA and protein expression levels of PRKCI in one osteosarcoma cell line (U2OS), one human osteoblast cell line (Saos2), and one human chondrosarcoma cell line (SW1353) were detected by RT-PCR and Western blot analyses. Results showed that PRKCI was overexpressed obviously in osteosarcoma and chondrosarcoma cell lines compared with osteoblast lines ( Figures 1A–C ), which indicated that PRKCI might play an important role in osteosarcoma tumorigenesis. Figure 1 PRKCI was upregulated in osteosarcoma cell lines. (A, B) The mRNA and protein expression levels of PRKCI were detected by RT-PCR and Western blot in U2OS, Saos2, and SW1353 cells. (C) Quantification of PRKCI protein amounts relative to ACTB in the osteosarcoma cell lines ( * p < 0.05). 3.2 Overexpression of PRKCI promotes osteosarcoma cell proliferation in vitro In order to explore the role of PRKCI in osteosarcoma cells, the effect of PRKCI-overexpression on the proliferation of osteosarcoma cells (SW1353 and U2OS) was studied by the CCK-8 assay and colony-forming assay. Figures 2A–D show that PRKCI was overexpressed in osteosarcoma cells after plasmid transfection. Figures 2E, F show that osteosarcoma cells transfected with the PRKCI plasmid had stronger proliferation ability than cells transfected with an empty vector ( p < 0.05), which was time-dependent. From Figures 2G–J , we learned that the number of clones in the PRKCI-overexpression group was significantly higher than that in the empty vector group ( p < 0.01), indicating that the overexpression of PRKCI significantly increased the colony-forming capacity of cells (SW1353 and U2OS). Figure 2 Overexpression of PRKCI promotes osteosarcoma cell growth in vitro . (A–D) Levels of mRNA and protein expression were validated by RT-PCR and Western blot in SW1353 and U2OS cells transfected with empty vector or PRKCI plasmid for 24 h, respectively. (E , F) CCK-8 assay was performed in SW1353 and U2OS cells after transfection. (G–J) Colony-forming assay was performed in osteosarcoma cells with or without PRKCI overexpression. (Data were representative of results from three independent experiments, * p < 0.05, ** p < 0.01). 3.3 Knockdown of PRKCI inhibits osteosarcoma cell proliferation in vitro In order to further clarify the effect of PRKCI on the biological characteristics of osteosarcoma cells, the changes in SW1353 and U2OS cell proliferation after silencing PRKCI were investigated. We identified two effective shRNAs against PRKCI (PRKCI shRNA1 and PRKCI shRNA2) that had similar effects in a previous paper published by our lab ( 21 ). Here, we used PRKCI shRNA2 as the representative shRNA to perform the subsequent experiments. RT-PCR and Western blot assays were used to verify the gene knockdown of PRKCI. The mRNA and protein expression levels of PRKCI were significantly decreased after transfection with PRKCI-specific shRNA in SW1353 and U2OS cells ( Figures 3A–D ). Subsequently, the CCK-8 assay showed that knockdown of PRKCI significantly inhibited the growth of osteosarcoma cells with time dependence ( Figures 3E, F ). Results of colony-forming assay revealed that the number and size of colonies were both obviously decreased in the PRKCI-knockdown group compared with the control group ( Figures 3G–J ). These results made clear that PRKCI played an oncogenic role in osteosarcoma. Figure 3 Knockdown of PRKCI inhibited osteosarcoma cell growth in vitro . (A–D) Levels of mRNA and protein expression of PRKCI were validated by RT-PCR and Western blot in SW1353 and U2OS cells transfected with shcontrol or shPRKCI for 48 h. (E , F) CCK-8 assay was performed after shRNA transfection. (G–J) Colony-forming assay was performed in osteosarcoma cells with or without PRKCI-silenced. (Data were representative of results from three independent experiments, * p < 0.05, ** p < 0.01). 3.4 Knockdown of PRKCI arrests cell cycle at G2/M phase in osteosarcoma cells Flow cytometry was used to determine the changes in the cell cycle in osteosarcoma cells after the knockdown of PRKCI. Results revealed that shPRKCI-transfected cells had a significantly higher percentage of cells in the G2/M phase than that of shcontrol-transfected cells in SW1353 ( Figures 4A, B ). Meanwhile, there was no significant difference in the G1 or S cell populations between PRKCI-knockdown and control-transfected cells. In U2OS cells, silencing PRKCI did not significantly induce G2/M ce...

## Figure captions
1. Figure 1. PRKCI was upregulated in osteosarcoma cell lines. (A, B) The mRNA and protein expression levels of PRKCI were detected by RT-PCR and Western blot in U2OS, Saos2, and SW1353 cells. (C) Quantification of PRKCI protein amounts relative to ACTB in the osteosarcoma cell lines ( * p < 0.05).
2. Figure 2. Overexpression of PRKCI promotes osteosarcoma cell growth in vitro . (A–D) Levels of mRNA and protein expression were validated by RT-PCR and Western blot in SW1353 and U2OS cells transfected with empty vector or PRKCI plasmid for 24 h, respectively. (E , F) CCK-8 assay was performed in SW1353 and U2OS cells after transfection. (G–J) Colony-forming assay was performed in osteosarcoma cells with or without PRKCI overexpression. (Data were representative of results from three independent experiments, * p < 0.05, ** p < 0.01).
3. Figure 3. Knockdown of PRKCI inhibited osteosarcoma cell growth in vitro . (A–D) Levels of mRNA and protein expression of PRKCI were validated by RT-PCR and Western blot in SW1353 and U2OS cells transfected with shcontrol or shPRKCI for 48 h. (E , F) CCK-8 assay was performed after shRNA transfection. (G–J) Colony-forming assay was performed in osteosarcoma cells with or without PRKCI-silenced. (Data were representative of results from three independent experiments, * p < 0.05, ** p < 0.01).
4. Figure 4. Knockdown of PRKCI-arrested cell cycle at G2/M phase in osteosarcoma cells. The cell cycle results of SW1353 (A) and U2OS (B) cells transfected with shcontrol or shPRKCI for 48 h were analyzed by flow cytometry. (C, D) Diagrams showing the results of the cell cycle assays for SW1353 and U2OS cells treated as in (A) . * p < 0.05, n.s., no significant differences.
5. Figure 5. The Transwell system was used to evaluate the effect of PRKCI on the migration and invasion of osteosarcoma cells. (A , C) Transwell migration assay and Matrigel invasion assay for SW1353 cells or U2OS cells after transfection empty vector or PRKCI plasmid for 24 h (shcontrol or shPRKCI for 48 h). Cells were stained with crystal violet (magnification: ×200). (B , D) Quantification of invaded and migrated SW1353 cells or U2OS cells. (Data were based on three independent experiments and shown as the mean ± SEM, ** p < 0.01).
6. Figure 6. A wound-healing assay was used to evaluate the effect of PRKCI on the migration of osteosarcoma cells. (A, B) Microscopic images of wound-healing assay data for SW1353 and U2OS cells transfected with empty vector or PRKCI plasmid for 24 h (shcontrol or shPRKCI for 48 h). (Data were based on three independent experiments and shown as the mean ± SEM, **p < 0.01).
7. Figure 7. The expression of PRKCI in patients with osteosarcoma. (A–C) Representative IHC image of PRKCI expression in nontumor adjacent tissues, chondrosarcoma tissues, and osteoblastic osteosarcoma tissues. (Original magnification: ×50 and ×200).
8. Figure 8. Knockdown of PRKCI inhibited the Akt-mTOR signaling pathway in osteosarcoma cells. (A, B) Western blot analysis of the Akt-mTOR signaling pathway, including total and phosphorylation levels of mTOR (Ser2448) and Akt (Ser473), in SW1353 and U2OS cells transfected with shcontrol or shPRKCI for 48 h (C, D) Quantification of the relative amounts of phosphorylated mTOR (p-mTOR) to total mTOR, phosphorylated AKT (p-AKT) to total AKT, and PRKCI to ACTB (β-actin) in SW1353 and U2OS cells transfected with indicated plasmids. Data are shown as the mean ± SEM of at least three independent ex...

## Table snippets
1. Table 1. Comparison of PRKCI protein expression in osteosarcoma and cancer-adjacent tissues. | Groups; N; PRKCI expression; p -value; 0; 1
2. Table 2. Comparison of SQSTM1 protein expression in osteosarcoma cancer and cancer-adjacent tissues. | Groups; N; SQSTM1 Expression; p -value; 0; 1
3. Table 3. The correlation between PRKCI expression and clinical characteristics of osteosarcoma patients. | Variables; Cases; PRKCI lower expression ( n = 8); PRKCI higher expression ( n = 34); p -value; N
4. Table 4. Relationship between SQSTM1 expression level and clinicopathological features in osteosarcoma ( n = 20). | Variables; Cases; SQSTM1 lower expression ( n = 7); SQSTM1 higher expression ( n = 13); p -value; N

## Candidate output (to be judged)

Methods

**Cell lines and culture**
The human osteosarcoma cell lines U2OS and SW1353, and the human osteoblastic cell line Saos2 were used. The specific culture conditions are not detailed in the provided evidence.

**Analysis of PRKCI expression**
The mRNA and protein expression levels of PRKCI in U2OS, Saos2, and SW1353 cells were evaluated using reverse transcription PCR (RT-PCR) and Western blot analysis, as shown in Fig. 1A-C. Protein levels were quantified relative to ACTB (β-actin).

**Plasmid and shRNA transfection**
For overexpression, SW1353 and U2OS cells were transfected with a PRKCI plasmid or an empty vector for 24 hours, with validation by RT-PCR and Western blot (Fig. 2A-D). For knockdown, cells were transfected with a PRKCI-specific shRNA (shPRKCI2) or a control shRNA (shcontrol) for 48 hours, as validated in Fig. 3A-D. The specific sequences and transfection reagents are not provided in the evidence.

**Functional assays**
Cell proliferation was assessed using the CCK-8 assay at multiple time points (Fig. 2E, F; Fig. 3E, F). Colony-forming capacity was measured by colony formation assay (Fig. 2G-J; Fig. 3G-J). Cell cycle distribution was analyzed by flow cytometry 48 hours after shRNA transfection (Fig. 4A-D). Cell migration and invasion were evaluated using Transwell migration and Matrigel invasion assays (Fig. 5), and a wound-healing assay (Fig. 6). For Transwell and wound-healing assays, cells were transfected with overexpression or knockdown constructs for 24 or 48 hours, respectively, as indicated in the figure captions for Fig. 5 and Fig. 6. All functional assays were performed in three independent experiments.

**Immunoprecipitation and pathway analysis**
The interaction between PRKCI and SQSTM1 was explored using immunoprecipitation, though the specific protocol is not detailed in the evidence. The effect of PRKCI knockdown on the Akt/mTOR signaling pathway was detected by Western blot analysis of total and phosphorylated levels of mTOR (Ser2448) and Akt (Ser473) in SW1353 and U2OS cells transfected for 48 hours (Fig. 8A-D).

**Clinical sample analysis**
Protein expression of PRKCI and SQSTM1 in osteosarcoma tissues, chondrosarcoma tissues, and adjacent nontumor tissues was assessed by immunohistochemistry (IHC), as represented in Fig. 7A-C. The correlation of PRKCI and SQSTM1 expression with clinical characteristics was analyzed, with data summarized in Table 3 and Table 4, respectively. The specific scoring criteria for IHC are not provided in the evidence.

**Statistical analysis**
Data are presented as the mean ± SEM from at least three independent experiments. Statistical significance is denoted as *p < 0.05 and **p < 0.01 in the figures. The specific statistical tests used are not detailed in the provided evidence.

## Output format

Respond with ONLY a single JSON object. No prose before or after. No markdown code fences. The JSON must match this schema exactly:

{
  "axis_scores": {
    "writing_structure_compliance": <float 0.0-1.0>,
    "evidence_grounding": <float 0.0-1.0>,
    "factual_fidelity": <float 0.0-1.0>,
    "traceability": <float 0.0-1.0>,
    "hallucination_absence": <float 0.0-1.0>
  },
  "axis_rationales": {
    "writing_structure_compliance": "<1-3 sentences>",
    "evidence_grounding": "<1-3 sentences>",
    "factual_fidelity": "<1-3 sentences>",
    "traceability": "<1-3 sentences>",
    "hallucination_absence": "<1-3 sentences>"
  },
  "grounding_issues": [
    "<specific concern citing the exact claim and why it is unsupported or inconsistent with the evidence>"
  ],
  "overall_pass": <true or false>
}